Cover Image
Market Research Report

Biosimilar Insulin Market Access

Published by Datamonitor Healthcare Product code 498961
Published Content info 19 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biosimilar Insulin Market Access
Published: January 26, 2018 Content info: 19 Pages
Description

Overview

Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba. More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.

Table of Contents
Product Code: DMKC0170584

TABLE OF CONTENTS

EXECUTIVE SUMMARY

  • US
  • Insights and strategic recommendations
  • US payers are adopting a wait-and-see approach for biosimilar Basaglar
  • Bibliography

FIVE MAJOR EU MARKETS

  • Insights and strategic recommendations
  • Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
  • Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to reduce costs
  • Payers use biosimilars to pressure originators on pricing
  • Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
  • Patient switching requires significant discounts of at least 30%
  • Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
  • Bibliography

METHODOLOGY

  • Primary research

LIST OF TABLES

  • Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Back to Top